
Leveling the Field in Canada

Are you being denied provincial pharmacare reimbursement coverage for biologic therapy to treat your rheumatoid arthritis?

If your answer is "Yes", we encourage you to speak out and fight for your patient rights.



Here's what you can do to help:

- 1. Look up your province's ranking below
- 2. Visit www.jointhealth.org and click on JointHealth™ Report Card to learn more about the differences in biologic therapy provincial reimbursement coverage for people with rheumatoid arthritis
- **3.** Write a letter to your provincial Minister of Health and provincially elected representative to advocate for improved reimbursement coverage

Biologic Therapies Reimbursement Rating	Province	Detailed Remarks
Good	BC SK	 Provides Special Authority reimbursement for 5 out of 7 biologic therapies approved by Health Canada for use in rheumatoid arthritis. Least restrictive Special Authority reimbursement criteria (e.g. fewest other medication failures required, and no interference in prescribing order). Shortest wait times for initial processing of Special Authority reimbursement applications. Fewest number of Special Authority reimbursement renewal applications required. Formal or informal appeal mechanism in place for Special Authority reimbursement coverage denials.
Average	AB ON QC NB NS	 Provides Special Authority reimbursement for 5 out of 7 biologic therapies approved by Health Canada for use in rheumatoid arthritis. Somewhat restrictive Special Authority reimbursement criteria (e.g. other medication failures required, some interference in prescribing order). Longer wait times for initial processing of Special Authority reimbursement applications. Special Authority reimbursement renewal applications required before one full year of coverage expires. No transparent appeal mechanism in place for Special Authority reimbursement coverage denials.
Poor	MB NFLD NIHB NT NU PEI YT	 Provides Special Authority reimbursement for 4 out of 7 biologic therapies approved by Health Canada for use in rheumatoid arthritis. Overly restrictive Special Authority reimbursement criteria (e.g. other medication failures required, interference in prescribing order). Longest wait times for initial processing of Special Authority reimbursement applications. Special Authority reimbursement renewal applications required before one full year of coverage expires. No appeal mechanism in place for Special Authority reimbursement coverage denials.